Octapharma LEX-210
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor prothrombin complex concentrate, OCTAPLEX, in patients鈥�
- Investigator
- T. Everett Jones
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Phase 3 Trial of PROTHROMPLEX TOTAL for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoag
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with鈥�
- Investigators
- T. Everett Jones, Yong G Peng
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
